Figure 1.

SMAPs inhibit tumor growth and decrease c-MYC expression in a model of Burkitt's lymphoma. A, tumor growth in a xenograft model of Burkitt's lymphoma with the Daudi cell line treated with DMA (control) or 15 mg/kg SMAP1 by oral gavage twice a day. B, change in individual tumor volume at end of study. C, Western blotting for c-MYC expression from tumor lysates. D, quantification of p-MYC (Ser⁶²) and MYC expression normalized to total protein. Stain-free images used for normalization are included in Fig. S3A. E, representative images of TUNEL staining in tumors treated with DMA or SMAPs. F, quantification of TUNEL. Respective quantifications are represented as means ± S.E. (A) or means ± S.D. (D and E). **, p < 0.01; ****, p < 0.0001. BID, twice per day; DAPI, 4′,6′-diamino-2-phenylindole.